Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis

This cross-sectional study compares price data for ocrelizumab and rituximab to estimate the savings to Medicare and Medicaid if rituximab were used in the treatment of multiple sclerosis instead of the higher-priced ocrelizumab.
Source: JAMA Neurology - Category: Neurology Source Type: research